GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
| 
                               
                            
                                
                                                                Synonyms: BMS-650032 | BMS650032 | compound 24 [PMID: 24564672] | Sunvepra™
                                 
                                                         
                            
                            
                            
                                 
                                
                                asunaprevir is an approved drug (Japan (2014), Canada (2016)) 
                                                        
                                                    
                                Compound class: 
                                                            Synthetic organic
                                 
                                
                                    
                                        Comment: Asunaprevir (BMS-650032) is an orally bioavailable, oligopeptide-based inhibitor of the nonstructural protein 3 (NS3), from hepatitis C virus (HCV) [4]. NS3, is a serine protease that is essential for proteolytic cleavages within the HCV polyprotein, a function that is key during HCV viral RNA replication. More recently asunaprevir has been reported to inhibit the papain-like protease (PL-pro, nsp3) in a number of coronaviruses [2].
                                    
                                 
                            
                            
                          
                                
                                    
                                
                          
                                   
                                   
                                  
                                      
                                     
                                   
                                   
                                    
                                    
                                     | 
                                    
                                        
                                         
  | 
                                    
                                
                                |||||||||||||||||||||||||||||||||||